![]() |
市場調查報告書
商品編碼
2088921
數位糖尿病管理市場:2026-2032年全球市場預測(依產品類型、交付方式、最終用戶、應用程式和銷售管道)Digital Diabetes Management Market by Product Type, Delivery Method, End User, Application, Sales Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,數位糖尿病管理市場將成長至 798.6 億美元,複合年成長率為 19.71%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 226.6億美元 |
| 預計年份:2026年 | 272.5億美元 |
| 預測年份 2032 | 798.6億美元 |
| 複合年成長率 (%) | 19.71% |
數位化糖尿病管理正逐漸成為慢性病照護的核心組成部分,它整合了持續血糖監測、連網血糖儀、胰島素幫浦、智慧胰島素筆、行動應用程式、遠距遠端醫療、健康指導和分析平台。這些技術幫助第1型糖尿病、第2型糖尿病和妊娠糖尿病患者即時監測血糖值、堅持服藥、追蹤生活方式習慣、接受遠端臨床評估並管理自身健康。
這項需求得到了全球疾病負擔的強力支撐。根據國際糖尿病聯盟(IDF)估計,2021年全球有5.37億糖尿病患者,預計2030年將達到6.43億,到2045年將達到7.83億。世界衛生組織(WHO)也已將糖尿病列為失明、腎衰竭、心臟病、中風和下肢截肢的主要原因之一,因此,擴充性的、數據驅動的糖尿病護理已成為醫療服務提供者、保險公司、雇主、醫療設備製造商以及數位健康領域相關人員的策略重點。
數位糖尿病管理領域正從間歇性的、以診所為中心的護理模式轉向持續性的、以患者為中心的糖尿病管理模式。聯網醫療設備現在可以即時產生血糖值、用藥依從性、活動水平、營養狀況和行為等方面的數據,從而實現更早的干預、更個性化的護理路徑以及在兩次就診之間提供更有力的支持。
人工智慧 (AI) 正在透過預測血糖值警報、胰島素劑量決策支援、自動模式識別、飲食和活動建議以及風險分層,重塑數位糖尿病管理。 AI 平台有助於識別存在低血糖風險、高血糖模式、藥物依從性問題、生活型態相關因素的患者,以及可能受益於臨床追蹤或治療調整的患者。
亞太地區是長期數位化糖尿病管理最重要的地區之一。這是因為中國和印度擁有絕大多數糖尿病患者,並且正在大力推廣行動優先的醫療模式、互聯監測和慢性病管理平台。北美地區仍然是數位化糖尿病管理應用的領先地區,這得益於連網型設備的普及、遠端醫療遠端患者監護的保險報銷、遠距醫療的建立以及對軟體賦能型醫療設備的積極法律規範。在以巴西和墨西哥為首的拉丁美洲,隨著醫療體系適應都市化、肥胖、心血管代謝風險以及專科醫生短缺等問題,數位化糖尿病管理的普及程度也不斷提高。
在東協市場,智慧型手機普及率的不斷提高以及各國政府加強非傳染性疾病預防項目,凸顯了行動端糖尿病教育、遠端監測、藥屋主導的患者參與以及基層醫療支持的重要性日益凸顯。在海灣合作理事會(GCC)國家,各國正增加對數位健康基礎設施、專業醫療保健系統、肥胖預防以及國家級糖尿病控制的投資,以應對高心血管代謝風險。歐盟透過醫療設備法規、資料保護規則、互通性政策和跨境數位健康計劃,為實證實踐的應用提供了系統的舉措。
美國是數位化糖尿病管理應用的主要市場之一,根據美國疾病管制與預防中心(CDC)報告,2021年美國有3,840萬名糖尿病患者,持續血糖監測、遠端監測、遠端醫療和雇主提供的數位化醫療服務應用廣泛。在加拿大,各省的糖尿病計畫和互聯醫療計畫正在應用。同時,墨西哥和巴西面臨糖尿病盛行率上升和醫療服務取得不均的雙重挑戰,因此兩國更加重視經濟實惠的互聯監測、行動教育和藥屋主導的醫療服務。在英國,國家醫療服務體系(NHS)關於治療路徑和糖尿病技術的國家指南正在充分利用。在德國、法國、義大利和西班牙,重點是在公共醫療體系和既有的慢性病管理框架內,以符合監管規定和實證醫學為基礎進行實施。
產業領導者應優先考慮經臨床驗證的數位化糖尿病解決方案,這些方案需能有效改善糖化血紅蛋白(HbA1c)水平、延長血糖達標時間、減少低血糖發生、提高用藥依從性、預防急性事件、增強患者參與度並降低整體醫療成本。與電子健康記錄、持續血糖檢驗系統、胰島素輸注設備、藥房系統、遠端醫療平台和保險公司工作流程的互通性應作為核心產品需求進行設計,而非事後考慮。
本執行摘要經濟合作暨發展組織研究方法編寫,所用資料皆來自公開可靠的來源,包括國際糖尿病聯盟(IDF)、世界衛生組織(WHO)、美國疾病管制與預防中心(CDC)、美國食品藥物管理局(FDA)、經濟合作暨發展組織(OECD)、各國衛生組織、監管機構、以及同儕審查的臨床文獻。分析重點在於與數位化糖尿病管理資訊來源的檢驗研究途徑,例如疾病負擔、技術採納、醫療服務模式、報銷政策和監管方向。
數位化糖尿病管理正從一種可有可無的輔助技術發展成為慢性病管理體系中不可或缺的一部分。糖尿病盛行率的上升、持續血糖監測的廣泛應用、遠端醫療胰島素輸注以及人工智慧分析技術的進步,正在建立一個更協調、預防性和個人化的糖尿病照護模式。
The Digital Diabetes Management Market is projected to grow by USD 79.86 billion at a CAGR of 19.71% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 22.66 billion |
| Estimated Year [2026] | USD 27.25 billion |
| Forecast Year [2032] | USD 79.86 billion |
| CAGR (%) | 19.71% |
Digital diabetes management is becoming a core layer of chronic disease care, combining continuous glucose monitoring, connected blood glucose meters, insulin pumps, smart insulin pens, mobile apps, telehealth, coaching, and analytics platforms. These technologies support real-time glucose visibility, medication adherence, lifestyle tracking, remote clinical review, and personalized self-management for people living with type 1, type 2, and gestational diabetes.
Demand is supported by a measurable global disease burden. The International Diabetes Federation estimated 537 million adults living with diabetes in 2021, with projections reaching 643 million by 2030 and 783 million by 2045. The World Health Organization also identifies diabetes as a major cause of blindness, kidney failure, heart attacks, stroke, and lower-limb amputation, making scalable, data-enabled diabetes care a strategic priority for providers, payers, employers, device manufacturers, and digital health stakeholders.
The digital diabetes management landscape is shifting from episodic, clinic-centered care toward continuous, patient-centered diabetes management. Connected devices now generate real-time glucose, medication, activity, nutrition, and behavioral data, enabling earlier intervention, more personalized care pathways, and stronger support between clinical visits.
Reimbursement expansion, remote patient monitoring programs, value-based care models, and consumer adoption of wearables are accelerating this transformation. At the same time, interoperability requirements, cybersecurity expectations, clinical evidence standards, and evolving medical device regulations are raising the bar for vendors seeking durable clinical, regulatory, and commercial adoption.
Artificial intelligence is reshaping digital diabetes management through predictive glucose alerts, insulin dose decision support, automated pattern recognition, food and activity insights, and risk stratification. AI-enabled platforms can help identify hypoglycemia risk, hyperglycemia patterns, medication nonadherence, lifestyle triggers, and patients who may benefit from clinical outreach or therapy adjustment.
The cumulative impact is strongest when AI is combined with validated devices, clinician oversight, transparent model design, and explainable workflows. Because diabetes care involves safety-critical decisions, industry leaders must prioritize algorithm validation, bias monitoring, data privacy, cybersecurity, post-market performance monitoring, and regulatory alignment before scaling autonomous or semi-autonomous capabilities.
Asia-Pacific represents one of the most important long-term digital diabetes management regions because China and India account for substantial diabetes populations and are scaling mobile-first healthcare models, connected monitoring, and chronic disease platforms. North America remains a leading adoption environment, supported by connected device penetration, remote patient monitoring reimbursement, telehealth normalization, and active regulatory oversight of software-enabled medical tools. Latin America, led by Brazil and Mexico, is expanding digital diabetes access as health systems respond to urbanization, obesity, cardiometabolic risk, and specialist shortages.
Europe benefits from structured diabetes care, public health system engagement, GDPR-driven data governance, and stronger evaluation standards for digital therapeutics and connected medical devices. The Middle East is advancing smart hospital, national digital health, and prevention programs, especially across GCC markets where diabetes and obesity are major policy priorities. Africa is earlier in adoption but offers meaningful potential through mobile health, community care, pharmacy networks, and lower-cost connected monitoring models that can extend diabetes support beyond specialist clinics.
ASEAN markets are increasingly relevant for mobile-enabled diabetes education, remote monitoring, pharmacy-led engagement, and primary care support as smartphone access expands and governments strengthen noncommunicable disease programs. GCC countries are investing in digital health infrastructure, specialty care capacity, obesity prevention, and national diabetes initiatives to address high cardiometabolic risk. The European Union provides a structured environment for evidence-based adoption through medical device regulation, data protection rules, interoperability policy, and cross-border digital health initiatives.
BRICS economies combine large diabetes populations with diverse reimbursement maturity, creating opportunities for scalable, localized, multilingual, and lower-cost digital diabetes platforms. G7 markets remain central for clinical validation, premium connected devices, reimbursement innovation, and integration with mature health systems. NATO members add a strategic focus on cyber resilience, secure health data exchange, emergency preparedness, and continuity of care across critical healthcare infrastructure.
The United States is a primary digital diabetes management adoption market, with the CDC reporting 38.4 million people with diabetes in 2021 and strong uptake of continuous glucose monitoring, remote monitoring, telehealth, and employer-sponsored digital care. Canada benefits from provincial diabetes programs and connected care initiatives, while Mexico and Brazil face rising prevalence and access gaps that favor affordable connected monitoring, mobile education, and pharmacy-enabled care. The United Kingdom leverages NHS pathways and national guidance for diabetes technology, while Germany, France, Italy, and Spain emphasize regulated, evidence-based adoption within public health systems and established chronic care frameworks.
Russia remains shaped by regional access variation, local procurement dynamics, and uneven digital health infrastructure. China and India offer major scale through mobile health ecosystems, expanding chronic care infrastructure, and large populations requiring earlier diagnosis and ongoing monitoring. Japan, Australia, and South Korea show strong readiness for connected devices, aging-population care models, digitally supported self-management, and integration of diabetes technology into broader preventive health and remote care strategies.
Industry leaders should prioritize clinically validated digital diabetes solutions that demonstrate improvements in HbA1c, time in range, hypoglycemia reduction, medication adherence, acute event prevention, patient engagement, and total cost of care. Interoperability with electronic health records, continuous glucose monitoring systems, insulin delivery devices, pharmacy systems, telehealth platforms, and payer workflows should be designed as a core product requirement rather than an afterthought.
Organizations should also strengthen AI governance, cybersecurity, health equity, accessibility, and localization strategies. Winning models will combine patient engagement, clinician workflow efficiency, reimbursement evidence, multilingual support, data protection compliance, and partnerships with health systems, payers, employers, pharmacies, and device manufacturers to deliver measurable outcomes across diverse care settings.
This executive summary is developed through a structured secondary research approach using publicly available and recognized sources, including the International Diabetes Federation, World Health Organization, CDC, FDA, OECD, national health agencies, regulatory bodies, and peer-reviewed clinical literature. The analysis focuses on verified indicators relevant to digital diabetes management, including disease burden, technology adoption, care delivery models, reimbursement policies, and regulatory direction.
Insights are triangulated across diabetes prevalence, connected device adoption, telehealth implementation, remote patient monitoring use cases, data governance requirements, and digital health deployment patterns. Market interpretation emphasizes verified evidence, regional comparability, and practical implications for stakeholders operating across devices, software, analytics, telehealth, coaching, pharmacy care, and chronic disease management services.
Digital diabetes management is moving from optional support technology to an essential component of chronic disease infrastructure. Rising diabetes prevalence, expanding continuous glucose monitoring adoption, telehealth normalization, connected insulin delivery, and AI-enabled analytics are creating a more connected, proactive, and personalized model of diabetes care.
The strongest opportunities will emerge where clinical evidence, regulatory trust, reimbursement readiness, interoperability, cybersecurity, and patient-centered design align. Organizations that deliver secure, equitable, accessible, and measurable solutions will be best positioned to support the next phase of digital diabetes care across health systems, payers, employers, clinicians, and patients.